{"id":11250,"date":"2019-07-15T00:00:00","date_gmt":"2019-07-15T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/"},"modified":"2025-08-19T08:28:21","modified_gmt":"2025-08-19T13:28:21","slug":"sante-canada-approuve-un-traitement-triple-incluant-pomalyst","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/","title":{"rendered":"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST"},"content":{"rendered":"<p>Le 10 juillet, 2019, Celgene Inc. annon\u00e7ait que Sant\u00e9 Canada a approuv\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\u00e9zomib et la dexam\u00e9thasone. Il s\u2019agit d\u2019une nouvelle option de traitement pour les patients atteints d\u2019un my\u00e9lome multiple ayant d\u00e9j\u00e0 re\u00e7u au moins un sch\u00e9ma th\u00e9rapeutique qui incluait le Revlimid (l\u00e9nalidomide).<\/p>\n<p>Dre Reece du&nbsp;Princess Margaret Cancer Centre&nbsp;d\u00e9clarait \u00ab le traitement triple incluant le pomalidomide constitue un progr\u00e8s important pour le traitement des patients atteints d\u2019un my\u00e9lome et leurs proches. \u00bb<\/p>\n<p>\ufeffBien que ce nouveau m\u00e9dicament soit disponible et que la vente ait \u00e9t\u00e9 approuv\u00e9e au Canada, il n\u2019est pas encore couvert par les r\u00e9gimes provinciaux.<\/p>\n<p><a href=\"https:\/\/www.newswire.ca\/fr\/news-releases\/sante-canada-approuve-la-tritherapie-a-base-de-pomalyst-r-pour-les-patients-atteints-de-myelome-multiple-856727097.html\" target=\"_blank\" rel=\"noopener\">Lire le communiqu\u00e9 de presse<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le 10 juillet, 2019, Celgene Inc. annon\u00e7ait que Sant\u00e9 Canada a approuv\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\u00e9zomib et la dexam\u00e9thasone. Il s\u2019agit d\u2019une nouvelle option de traitement pour les patients atteints d\u2019un my\u00e9lome multiple ayant d\u00e9j\u00e0 re\u00e7u au moins un sch\u00e9ma th\u00e9rapeutique qui incluait le Revlimid (l\u00e9nalidomide). Dre [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[50,50,52,52],"tags":[],"class_list":["post-11250","post","type-post","status-publish","format-standard","hentry","category-news-events","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Le 10 juillet, 2019, Celgene Inc. annon\u00e7ait que Sant\u00e9 Canada a approuv\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\u00e9zomib et la dexam\u00e9thasone. Il s\u2019agit d\u2019une nouvelle option de traitement pour les patients atteints d\u2019un my\u00e9lome multiple ayant d\u00e9j\u00e0 re\u00e7u au moins un sch\u00e9ma th\u00e9rapeutique qui incluait le Revlimid (l\u00e9nalidomide). Dre\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Le 10 juillet, 2019, Celgene Inc. annon\u00e7ait que Sant\u00e9 Canada a approuv\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\u00e9zomib et la dexam\u00e9thasone. Il s\u2019agit d\u2019une nouvelle option de traitement pour les patients atteints d\u2019un my\u00e9lome multiple ayant d\u00e9j\u00e0 re\u00e7u au moins un sch\u00e9ma th\u00e9rapeutique qui incluait le Revlimid (l\u00e9nalidomide). Dre\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2019-07-15T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:21+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Le 10 juillet, 2019, Celgene Inc. annon\u00e7ait que Sant\u00e9 Canada a approuv\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\u00e9zomib et la dexam\u00e9thasone. Il s\u2019agit d\u2019une nouvelle option de traitement pour les patients atteints d\u2019un my\u00e9lome multiple ayant d\u00e9j\u00e0 re\u00e7u au moins un sch\u00e9ma th\u00e9rapeutique qui incluait le Revlimid (l\u00e9nalidomide). Dre\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#blogposting\",\"name\":\"SANT\\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST | My\\u00e9lome Canada\",\"headline\":\"SANT\\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2019-07-15T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:21-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#webpage\"},\"articleSection\":\"News &amp; Events, News &amp; Events, What's new at Myeloma Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#listItem\",\"name\":\"SANT\\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#listItem\",\"position\":4,\"name\":\"SANT\\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/\",\"name\":\"SANT\\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST | My\\u00e9lome Canada\",\"description\":\"Le 10 juillet, 2019, Celgene Inc. annon\\u00e7ait que Sant\\u00e9 Canada a approuv\\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\\u00e9zomib et la dexam\\u00e9thasone. Il s\\u2019agit d\\u2019une nouvelle option de traitement pour les patients atteints d\\u2019un my\\u00e9lome multiple ayant d\\u00e9j\\u00e0 re\\u00e7u au moins un sch\\u00e9ma th\\u00e9rapeutique qui incluait le Revlimid (l\\u00e9nalidomide). Dre\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/15\\\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2019-07-15T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:21-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST | My\u00e9lome Canada","description":"Le 10 juillet, 2019, Celgene Inc. annon\u00e7ait que Sant\u00e9 Canada a approuv\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\u00e9zomib et la dexam\u00e9thasone. Il s\u2019agit d\u2019une nouvelle option de traitement pour les patients atteints d\u2019un my\u00e9lome multiple ayant d\u00e9j\u00e0 re\u00e7u au moins un sch\u00e9ma th\u00e9rapeutique qui incluait le Revlimid (l\u00e9nalidomide). Dre","canonical_url":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#blogposting","name":"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST | My\u00e9lome Canada","headline":"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2019-07-15T00:00:00-05:00","dateModified":"2025-08-19T08:28:21-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#webpage"},"articleSection":"News &amp; Events, News &amp; Events, What's new at Myeloma Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#listItem","name":"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#listItem","position":4,"name":"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/","name":"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST | My\u00e9lome Canada","description":"Le 10 juillet, 2019, Celgene Inc. annon\u00e7ait que Sant\u00e9 Canada a approuv\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\u00e9zomib et la dexam\u00e9thasone. Il s\u2019agit d\u2019une nouvelle option de traitement pour les patients atteints d\u2019un my\u00e9lome multiple ayant d\u00e9j\u00e0 re\u00e7u au moins un sch\u00e9ma th\u00e9rapeutique qui incluait le Revlimid (l\u00e9nalidomide). Dre","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2019-07-15T00:00:00-05:00","dateModified":"2025-08-19T08:28:21-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST | My\u00e9lome Canada","og:description":"Le 10 juillet, 2019, Celgene Inc. annon\u00e7ait que Sant\u00e9 Canada a approuv\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\u00e9zomib et la dexam\u00e9thasone. Il s\u2019agit d\u2019une nouvelle option de traitement pour les patients atteints d\u2019un my\u00e9lome multiple ayant d\u00e9j\u00e0 re\u00e7u au moins un sch\u00e9ma th\u00e9rapeutique qui incluait le Revlimid (l\u00e9nalidomide). Dre","og:url":"https:\/\/myeloma.ca\/fr\/2019\/07\/15\/sante-canada-approuve-un-traitement-triple-incluant-pomalyst\/","article:published_time":"2019-07-15T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:21+00:00","twitter:card":"summary_large_image","twitter:title":"SANT\u00c9 CANADA APPROUVE UN TRAITEMENT TRIPLE INCLUANT POMALYST | My\u00e9lome Canada","twitter:description":"Le 10 juillet, 2019, Celgene Inc. annon\u00e7ait que Sant\u00e9 Canada a approuv\u00e9 un traitement triple comprenant le Pomalyst (pomalidomide) en association avec le bort\u00e9zomib et la dexam\u00e9thasone. Il s\u2019agit d\u2019une nouvelle option de traitement pour les patients atteints d\u2019un my\u00e9lome multiple ayant d\u00e9j\u00e0 re\u00e7u au moins un sch\u00e9ma th\u00e9rapeutique qui incluait le Revlimid (l\u00e9nalidomide). Dre"},"aioseo_meta_data":{"post_id":"11250","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 17:04:47","updated":"2026-04-30 07:29:56","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11250"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11250\/revisions"}],"predecessor-version":[{"id":31327,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11250\/revisions\/31327"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}